12:51 PM
 | 
Mar 15, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Apatinib: Ph III ANGEL started

LSK began the double-blind, placebo-controlled, international Phase III ANGEL trial to compare oral apatinib daily plus best supportive care (BSC) vs. BSC alone in about 459 patients who have failed ≥2 prior lines of standard...

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >